MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

11%

89%

16 / 349 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2026, 22:56 UTC

Uudisväärsed sündmused

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1. apr 2026, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1. apr 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1. apr 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1. apr 2026, 23:23 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1. apr 2026, 23:07 UTC

Tulu

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1. apr 2026, 23:02 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1. apr 2026, 22:39 UTC

Tulu

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1. apr 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1. apr 2026, 21:31 UTC

Uudisväärsed sündmused

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. apr 2026, 20:38 UTC

Tulu

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1. apr 2026, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1. apr 2026, 20:13 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1. apr 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1. apr 2026, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

16 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.